Due to an equipment failure the availability of albumin is currently limited
In accordance with the relevant authorities, Biotest decided that all batches which have been produced in the affected equipment and have already been supplied, must not be used until the issue is clarified.
Additional necessary analyses are currently conducted. The company expect results within the next four weeks. Biotest will take further steps on the basis of these analysis data. The impact on sales and annual results for the Biotest Group are only assessable afterwards.
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.